US2022153731A1PendingUtilityA1

Compounds for Pain Treatment, Compositions Comprising Same, and Methods of Using Same

Assignee: ACADIA PHARM INCPriority: May 29, 2018Filed: Jul 6, 2021Published: May 19, 2022
Est. expiryMay 29, 2038(~11.8 yrs left)· nominal 20-yr term from priority
C07D 417/12A61P 29/00A61K 31/4439A61P 25/04
70
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to compounds of formula (I), compositions containing the same, and methods for treating and/or diminishing pain in a subject in need thereof. The compounds of formula (I) are effective for treating opioid-induced tachyphylaxis and opioid-induced hyperalgesia.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A compound of formula (I), or a salt, solvate, enantiomer, diastereoisomer or tautomer thereof: 
       
         
           
           
               
               
           
         
       
       wherein:
 Y is selected from the group consisting of S, O, NH, NR, and CH 2 ; 
 R 1  is selected from the group consisting of H, C 1 -C 6  alkyl, C 3 -C 8  cycloalkyl, C 1 -C 6  alkenyl, C 1 -C 6  alkynyl, aryl, arylalkyl, heteroarylalkyl, and heteroaryl, wherein the alkyl, cycloalkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroarylalkyl, or heteroaryl group is independently optionally substituted; 
 R 2  is selected from the group consisting of H, —C(═O)H, —C(═O)—R, and —CH 2 —OR; 
 R 3  and R 4  are independently selected from the group consisting of H and optionally substituted C 1 -C 6  alkyl, or R 3  and R 4  can combine to form a C 1 -C 6  alkylene; 
 W is selected from the group consisting of H, C 1 -C 6  alkyl, C 3 -C 8  cycloalkyl, C 1 -C 6  alkoxy, C 1 -C 6  hydroxyalkyl, —CHO, —C(═O)OR, —C(═O)NRR, cyano, hydroxy, aryl, and heteroaryl, wherein the alkyl, alkoxy, cycloalkyl, aryl, or heteroaryl group is independently optionally substituted, and wherein each occurrence of R is independently H, C 1 -C 6  alkyl, and C 3 -C 8  cycloalkyl; and 
 each occurrence of R is independently selected from the group consisting of C 1 -C 6  alkyl and C 3 -C 8  cycloalkyl. 
 
     
     
         2 . The compound of  claim 1 , which is a compound of formula (Ia): 
       
         
           
           
               
               
           
         
       
     
     
         3 . The compound of  claim 2 , wherein R 2  is H. 
     
     
         4 . The compound of  claim 3 , wherein Y is S. 
     
     
         5 . The compound of  claim 4 , wherein W is selected from the group consisting of H, C 1 -C 6  hydroxyalkyl, —CHO, —C(═O)OR, and —C(═O)NRR, wherein the alkyl, alkoxy, cycloalkyl, aryl, or heteroaryl group is independently optionally substituted and wherein each occurrence of R is independently H, C 1 -C 6  alkyl, and C 3 -C 8  cycloalkyl. 
     
     
         6 . The compound of  claim 5 , wherein R 3  and R 4  are independently selected from the group consisting of H and C 1 -C 6  alkyl. 
     
     
         7 . The compound of  claim 1 , which is selected from the group consisting of:
 (R)-2-(3-Hydroxy-pyridin-2-ylamino)-5,5-dimethyl-4,5-dihydro-thiazole-4-carboxylic acid;   (S)-2-(3-Hydroxy-pyridin-2-ylamino)-5,5-dimethyl-4,5-dihydro-thiazole-4-carboxylic acid;   (R)-2-((3-hydroxypyridin-2-yl)amino)-4,5-dihydrothiazole-4-carboxylic acid; and   (S)-2-((3-hydroxypyridin-2-yl)amino)-4,5-dihydrothiazole-4-carboxylic acid.   
     
     
         8 . A pharmaceutical composition comprising the compound of  claim 1 . 
     
     
         9 . A pharmaceutical composition comprising the compound of  claim 7 . 
     
     
         10 . A method of preventing, reducing, or alleviating pain in a mammal, the method comprising administering a therapeutically effective amount of the compound of  claim 1  to the mammal. 
     
     
         11 . The method of  claim 10 , wherein the administration is oral, parenteral, nasal, inhalational, intravenous, subcutaneous, transdermal, or enteral. 
     
     
         12 . The method of  claim 10 , wherein the mammal is a human. 
     
     
         13 . The method of  claim 10 , wherein the pain is spontaneous pain. 
     
     
         14 . The method of  claim 10 , wherein the pain is hyperalgesia. 
     
     
         15 . The method of  claim 10 , wherein the pain is allodynia. 
     
     
         16 . The method of  claim 10 , wherein the pain arises from a surgical procedure. 
     
     
         17 . The method of  claim 16 , wherein the surgical procedure comprises third molar extraction, dental implants, lingual hernia repair, cholecystectomy, breast augmentation, abdominoplasty, vasectomy, hysterectomy, pacemaker implantation, and/or laparoscopic techniques. 
     
     
         18 . The method of  claim 10 , wherein the pain arises from trauma, sprains, broken bones, bruises, cuts, and/or burns. 
     
     
         19 . The method of  claim 10 , wherein the pain is neuropathic pain. 
     
     
         20 . The method of  claim 10 , wherein the pain is painful diabetic neuropathy. 
     
     
         21 . The method of  claim 10 , wherein the pain is chronic pain. 
     
     
         22 . The method of  claim 10 , wherein the pain arises from cancers, diabetes, Parkinson's Disease, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, and/or peripheral and/or central neuropathies. 
     
     
         23 . The method of  claim 10 , wherein the pain is caused by an inflammatory disease. 
     
     
         24 . The method of  claim 23 , wherein the inflammatory disease comprises rheumatoid arthritis, osteoarthritis, lupus, inflammatory bowel syndrome, vulvodynia, and/or Sjorgen's disease. 
     
     
         25 . The method of  claim 10 , wherein the pain is caused by cancer chemotherapy, cancer radiation treatment, stroke, and/or myocardial infarct.

Join the waitlist — get patent alerts

Track US2022153731A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.